SS-31 Peptide: Mechanism of Action, Research Overview, and Study Findings

What Is SS-31?

SS-31 is a synthetic, mitochondria-targeted tetrapeptide, also known by its clinical development name elamipretide, designed to concentrate in the inner mitochondrial membrane and stabilize cardiolipin — a phospholipid critical to mitochondrial energy production. The compound belongs to the Szeto-Schiller peptide family and carries an alternating aromatic-cationic amino acid motif that drives its selective accumulation at the inner membrane without requiring a membrane potential for uptake. Research on SS-31 spans both preclinical animal models and human randomized controlled trials, making it one of the more extensively studied mitochondria-targeted compounds in the peptide research space.

---

What Is SS-31 Studied For?

Research on SS-31 goes back to 2020 — 6 years — with studies continuing through 2025.

1. Primary Mitochondrial Myopathy — A phase III randomized controlled trial enrolling 218 participants (MMPOWER-3, 2023) evaluated elamipretide in individuals with primary mitochondrial myopathy and measured outcomes including six-minute walk distance and patient-reported fatigue scores.

2. Neuroinflammation and Cognitive Function — A 2020 mouse study reported that elamipretide improved mitochondrial dysfunction, synaptic signaling deficits, and memory impairment triggered by lipopolysaccharide-induced neuroinflammation.

3. Myocardial Ischemia-Reperfusion Injury — A 2025 preclinical study using H9C2 cardiomyocytes subjected to hypoxia/reoxygenation found that an SS-31-based formulation (SS-31@Fer-1) reduced ferroptosis — an iron-dependent form of cell death — via mitochondrial targeting.

4. Diabetic Kidney Disease — A 2024 rodent study found that SS-31 mitigated mitochondrial injury in podocytes by counteracting abnormal cardiolipin remodelling driven by the enzyme ALCAT1.

5. Age-Related Mitochondrial Decline — A 2023 rodent study reported that elamipretide improved ADP sensitivity in aged skeletal muscle mitochondria by increasing ADP uptake through the adenine nucleotide translocator (ANT).

---

How Does SS-31 Work?

SS-31 acts primarily by binding to cardiolipin on the inner mitochondrial membrane. Cardiolipin is a structurally unique, four-tailed phospholipid found almost exclusively at this site, where it anchors electron transport chain complexes and supports the curvature of cristae — the folded structures where ATP synthesis takes place. When cardiolipin becomes oxidized or remodelled abnormally, electron transport chain efficiency drops, reactive oxygen species (ROS) production rises, and mitochondrial membrane integrity deteriorates.

The peptide's alternating aromatic and cationic residues allow it to intercalate into the cardiolipin-rich inner membrane. By binding cardiolipin directly, SS-31 reduces its oxidation, stabilizes cristae architecture, and restores the spatial organization needed for efficient oxidative phosphorylation. This mechanism is upstream of many downstream pathologies — rather than scavenging individual ROS molecules after they form, the compound targets the structural source of excess ROS generation.

A 2023 rodent study published in GeroScience provided additional mechanistic granularity: elamipretide was found to bind directly to the adenine nucleotide translocator (ANT), increasing ADP uptake into aged mitochondria and thereby restoring ADP sensitivity that had been lost with aging. That study documented improved physiological function in aged mouse skeletal muscle alongside the bioenergetic changes, identifying ANT engagement as a distinct functional target beyond cardiolipin stabilization alone.

---

What Does Animal Research Show?

Preclinical studies have tested SS-31 across several organ systems and disease models, consistently linking its effects to mitochondrial stabilization.

Neuroinflammation model. A 2020 mouse study published in the Journal of Neuroinflammation used lipopolysaccharide (LPS) to induce systemic inflammation and measured downstream effects on brain mitochondrial function, synaptic structure, and memory. The study reported that elamipretide attenuated mitochondrial dysfunction, reduced oxidative damage at synapses, and improved memory performance on behavioral tests. The authors positioned the effects as downstream consequences of cardiolipin protection and reduced mitochondrial ROS.

Cardiac ischemia-reperfusion. A 2025 study in Biomedicine & Pharmacotherapy examined an SS-31-based conjugate (SS-31@Fer-1) in H9C2 cardiomyocytes exposed to hypoxia followed by reoxygenation — a standard in vitro model of ischemia-reperfusion injury. The study found that the compound reduced ferroptotic cell death through mitochondrial targeting, with SS-31 serving as the mitochondria-directing component of the conjugate. A separate 2022 study in Advanced Healthcare Materials used a reactive oxygen species-responsive hydrogel to deliver SS-31 in a rodent myocardial infarction model, reporting improved mitochondrial function in cardiomyocytes and enhanced angiogenesis at the infarct site.

Diabetic kidney disease. A 2024 rodent study in Cell Communication and Signaling examined how abnormal cardiolipin remodelling — driven by overexpression of the acyltransferase ALCAT1 — caused mitochondrial injury in podocytes, the specialized kidney cells that maintain the glomerular filtration barrier. SS-31 administration reduced that injury, consistent with its established role in preserving cardiolipin integrity. The study did not evaluate long-term renal functional outcomes.

Allergic airway inflammation. A 2025 rodent study in International Immunopharmacology investigated the role of the m6A reader protein YTHDF1 in a toluene diisocyanate-induced asthma model, finding that mitochondrial dysfunction mediated through β-catenin/TCF4 signaling contributed to steroid-insensitive airway inflammation. SS-31 was used to probe the mitochondrial component of that pathway. This represents a mechanistically adjacent application — mitochondrial dysfunction as a driver of inflammatory airway disease — rather than a direct therapeutic target studied in isolation.

Reproductive biology. A 2025 mouse study published in Nature Communications examined whether mitochondrial activity in early zygotes influences offspring telomere length. The study found that disrupting mitochondrial function in mouse zygotes shortened telomeres in offspring, and that SS-31 treatment during the zygote stage partially offset this effect. The finding positions mitochondrial quality during fertilization as a determinant of telomere inheritance — a result with significant mechanistic implications, though the translational distance from mice to humans remains large.

Aging skeletal muscle. The 2023 GeroScience rodent study mentioned in the mechanism section documented that aged mitochondria show reduced ADP sensitivity — meaning they respond less efficiently to energy demand signals. Elamipretide increased ADP uptake through ANT, improving the coupling between cellular energy demand and mitochondrial output. The study connected these mitochondrial changes to measurable improvements in muscle physiology in aged animals.

---

What Does Human Research Show?

The most rigorous human evidence for SS-31 comes from the MMPOWER-3 trial, a phase III randomized controlled trial published in Neurology in 2023. The trial enrolled 218 participants with confirmed primary mitochondrial myopathy (PMM) — a group of genetic disorders impairing oxidative phosphorylation — and evaluated elamipretide against placebo over 24 weeks. The primary endpoints were six-minute walk distance and a patient-reported fatigue measure.

MMPOWER-3 did not meet its co-primary endpoints: neither the functional walk test nor the fatigue score showed statistically significant improvement over placebo in the full trial population. The trial did report that elamipretide was generally well-tolerated, with an adverse event profile consistent with earlier-phase studies. The investigators noted variability in the PMM population and the challenges of measuring functional outcomes in a heterogeneous genetic disease group.

This result is an important calibration point. The preclinical evidence for elamipretide's mitochondrial mechanism is mechanistically coherent and replicated across multiple models. The MMPOWER-3 outcome illustrates that mechanistic plausibility in animal models and in vitro systems does not guarantee efficacy signals in human trials, particularly in genetically complex disease populations.

---

What Is Still Unknown?

Several questions remain open. MMPOWER-3's null result on primary endpoints in a single disease population does not resolve whether elamipretide might show different results in other mitochondrial disease subtypes, different dosing regimens, or patient subgroups with more homogeneous mitochondrial defects. The trial's own design acknowledged the heterogeneity challenge.

The mechanism work — particularly the ANT-binding finding from the 2023 GeroScience study and the zygote telomere work from the 2025 Nature Communications paper — opens questions about whether mitochondrial-targeted peptides like SS-31 have utility in age-related conditions beyond genetic myopathies. Those applications currently have only rodent-level evidence.

The cardiolipin-binding mechanism is well-characterized biochemically, but the degree to which stabilizing cardiolipin translates to clinically measurable outcomes in human tissue remains an active area. Formulation work — exemplified by the SS-31@Fer-1 conjugate and the hydrogel delivery system — suggests researchers are actively investigating whether delivery optimization can improve target engagement.

---

Where Can I Buy SS-31?

SS-31 is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---